Institutional members access full text with Ovid®

Share this article on:

New directions for HIV vaccine development from animal models

McChesney, Michael B.; Miller, Christopher J.

doi: 10.1097/COH.0b013e328363d3a2
CHANGING ENVIRONMENT IN HIV VACCINE: Edited by Nelson L. Michael and Glenda Gray

Purpose of review: The development of a preventive HIV vaccine remains an unresolved challenge. Animal models that can predict the results of HIV vaccine efficacy trials and identify the immune mechanisms responsible for vaccine protection would be most useful for HIV vaccine development. The purpose of the current review is to critique recent developments in the use of animal models of HIV infection in preclinical studies of AIDS vaccines and to describe how the use of improved animal models can inform the development of an HIV vaccine.

Recent findings: The results of preclinical experiments with candidate HIV vaccines can vary with the SIV challenge virus used. It is now known that there is considerable variability in the neutralization sensitivity and that the level of viral sequence diversity within the challenge stocks varies. This has allowed more realistic preclinical vaccine studies with heterologous vaccine antigens and challenge viruses. Further, the dose of challenge virus and the route of virus challenge can modify the efficacy of candidate vaccines in preclinical studies.

Summary: Recent experiments demonstrate that nonhuman primate models of AIDS can reproduce the complex biology of HIV transmission, recapitulate the results of HIV vaccine efficacy trials in humans and be used to identify correlates of protection.

aCalifornia National Primate Research Center

bCenter for Comparative Medicine, University of California, Davis, California, USA

Correspondence to Christopher J. Miller, CNPRC, UC Davis, One Shields Ave, Davis, CA 95616, USA. Tel: +1 530 752 0447; fax: +1 530 752 2880; e-mail: cjmiller@ucdavis.edu

Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.